Table 1 The baseline clinical characteristics and laboratory parameters of the patients
Variables | Group 1 n = 34 | Group 2 n = 49 | Group 3 n = 52 | *F | *p |
|---|---|---|---|---|---|
Age, years | 55.9 ± 12.9 | 49.9 ± 13.2 | 50.1 ± 14.2 | 2.428 | 0.092 |
Gender, male (%) | 23 (67.6) | 33 (67.3) | 30 (57.7) | - | 0.516 |
Atrial fibrillation, n (%) | 17 (50) | 28 (57.1) | 26 (50) | - | 0.727 |
Hypertension, n (%) | 16 (47.1) | 14 (28.6) | 19 (36.5) | - | 0.227 |
Diabetes mellitus, n (%) | 8 (23.5) | 5 (10.2) | 4 (7.7) | - | 0.079 |
Smoking, n (%) | 5 (20) | 15 (32.6) | 11 (21.6) | - | 0.360 |
Neurological dysfunction, n (%) | 3 (8.8) | 3 (6.1) | 2 (3.8) | - | 0.632 |
Follow-up time, months | 33.7 ± 29.0 | 40.4 ± 32.9 | 42.8 ± 31.5 | 0.884 | 0.416 |
Mean LVEF, % | 53.3 ± 9.8 | 53.2 ± 8.8 | 54.0 ± 9.2 | 0.778 | 0.461 |
Left atrium, cm | 5.2 ± 0.8 | 5.8 ± 1.0 | 5.5 ± 1.0 | 3.727 | 0.027 |
sPAP, mmHg | 40.8 ± 12.7 | 43.8 ± 14.7 | 42.2 ± 12.5 | 0.506 | 0.604 |
Hemoglobin, g/dL | 13.6 ± 1.5 | 12.7 ± 1.6 | 12.3 ± 1.3 | 7.899 | 0.001 |
WBC, ×103/μL | 7.8 ± 2.7 | 8.5 ± 2.2 | 7.7 ± 1.9 | 2.098 | 0.127 |
Platelet, ×103/μL | 196.91 ± 68.1 | 218.98 ± 77.7 | 231.77 ± 78.4 | 2.181 | 0.117 |
Creatinine, mg/dL | 1.24 ± 1.3 | 1.39 ± 1.5 | 0.9 ± 0.2 | 2.201 | 0.115 |
Mean INR level | 1.8 ± 0.1 | 2.2 ± 0.1 | 2.8 ± 0.3 | 232.346 | <0.001 |